Abstract
Major progress has been made in the treatment of older patients (≥65 years) with newly diagnosed multiple myeloma. To date, continuous lenalidomide-based regimens are considered as standard of care for transplantation-ineligible patients with newly diagnosed multiple myeloma.1 In the past 10 years, immunotherapy was established as a new cornerstone of myeloma therapy, in addition to proteasome inhibitors and immunomodulatory drugs. The incorporation of daratumumab, a monoclonal antibody targeting CD38, with lenalidomide and dexamethasone led to progression-free and overall survival improvement in older patients with newly diagnosed multiple myeloma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
